Early-life wheezing and respiratory syncytial virus prevention.

Robert F Lemanske
Author Information

Abstract

No abstract text available.

References

  1. BMJ. 2010 Oct 04;341:c4978 [PMID: 20921080]
  2. J Allergy Clin Immunol. 2012 Aug;130(2):489-95 [PMID: 22766097]
  3. Am J Respir Crit Care Med. 2012 Feb 1;185(3):281-5 [PMID: 21960534]
  4. Expert Rev Anti Infect Ther. 2011 Sep;9(9):731-45 [PMID: 21905783]
  5. N Engl J Med. 2013 Apr 11;368(15):1398-407 [PMID: 23534543]
  6. J Pediatr. 2007 Jul;151(1):34-42, 42.e1 [PMID: 17586188]
  7. Lancet. 2008 Sep 20;372(9643):1100-6 [PMID: 18805338]
  8. J Allergy Clin Immunol. 2010 Aug;126(2):256-62 [PMID: 20624638]
  9. J Allergy Clin Immunol. 2012 Aug;130(2):403-7.e5 [PMID: 22766098]
  10. N Engl J Med. 1995 Jan 19;332(3):133-8 [PMID: 7800004]
  11. Am J Respir Crit Care Med. 2008 Oct 1;178(7):667-72 [PMID: 18565953]
  12. N Engl J Med. 2013 May 9;368(19):1791-9 [PMID: 23656644]

Grants

  1. P01 HL070831/NHLBI NIH HHS
  2. R01 HL097134/NHLBI NIH HHS
  3. U10 HL098090/NHLBI NIH HHS

MeSH Term

Antibodies, Monoclonal, Humanized
Antiviral Agents
Female
Humans
Infant, Premature, Diseases
Male
Palivizumab
Respiratory Sounds
Respiratory Syncytial Virus Infections
Respiratory Syncytial Viruses

Chemicals

Antibodies, Monoclonal, Humanized
Antiviral Agents
Palivizumab

Word Cloud

Created with Highcharts 10.0.0Early-lifewheezingrespiratorysyncytialvirusprevention

Similar Articles

Cited By